Overview

Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
0
Participant gender:
All
Summary
Drug serum concentrations will be measured at several time-points for inflammatory disease patients treated with anti-TNF agents. The purpose is to determine which patients that will clinically benefit from either discontinue treatment, adjusting the dose, switch to another anti-TNF agent or a different class of medication.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Oslo University Hospital
Treatments:
Adalimumab
Certolizumab Pegol
Infliximab
Criteria
Inclusion Criteria:

- Patients diagnosed with Inflammatory bowel disease

- Treated with anti-TNF drug

- Follow-up at specialized gastroenterologist in Norway

- Age 18 or over

Exclusion Criteria:

- Patients refusing to participate by not giving their informed consent